Clinical Trial

Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease

Study acronym: ELEGANCE
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This observational study is designed to collect data on the use of the drug Lecigon® in daily clinical practice. The study is organised and funded by a pharmaceutical company called Britannia Pharmaceuticals Ltd (Britannia). Lecigon® is prescribed by physicians in advanced Parkinson's disease when patients suffer from uncontrollable fluctuations in mobility, so-called motor fluctuations, which cannot be adjusted well with oral treatment, i.e. medication for swallowing. In this study, data on the effect and possible side effects from everyday treatment with Lecigon® will be collected and scientifically evaluated. The study is intended to supplement the results of previous clinical studies with clinical data in routine medical care, collected from approximately 300 patients.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2021-09-03; most recent amendment 2026-04-22.
Status change: Recruiting → Active, Not Recruiting 2024-10-02
Trial Details
NCT Number NCT05043103
Lead Sponsor Britannia Pharmaceuticals Ltd.
Conditions Advanced Parkinson Disease
Enrollment 312 participants
Start Date 2021-07-06
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-23